This study suggests that targeting the IRF4-c-MYC axis, which remains challenging due to the lack of clinically useful targeted treatments, may offer novel therapeutic approaches not only for MM but also for other c-MYC-dependent cancer types [56]. Here, IRF4 is linked to Miyoshi myopathy.